Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T18632
(Former ID: TTDR01239)
|
|||||
Target Name |
Cholinergic receptor unspecific (CHR)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Tonus and reflex abnormality [ICD-11: MB47] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
1 | Cisatracurium | Drug Info | Approved | Muscle spasm | [2] | |
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | Sofpironium bromide | Drug Info | Phase 3 | Primary axillary hyperhidrosis | [3] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Antagonist | [+] 2 Antagonist drugs | + | ||||
1 | Cisatracurium | Drug Info | [1] | |||
2 | Sofpironium bromide | Drug Info | [4] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth. 1997 Dec;44(12):1286-92. | |||||
REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 3 | ClinicalTrials.gov (NCT03627468) A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis. U.S. National Institutes of Health. | |||||
REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.